About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 6641 record(s)
Req # A-2022-001480
Adverse Drug Reaction (ADR) for Sodium Chloride injection. Report number: E2B_05679330.Organization: Health Canada
November 2024
Req # A-2022-001486
Adverse Drug Reactions (ADRs). Report numbers: E2B_02121456, E2B_02093591, E2B_05935451, E2B_05887182, E2B_06026557.Organization: Health Canada
November 2024
Req # A-2022-001516
Adverse Drug Reactions (ADRs) for ENTYVIO. Report numbers: E2B_06001907, E2B_06017562, E2B_05989083, E2B_06030605, E2B_05975424, E2B_06010484, E2B_06028666, E2B_05996872, E2B_05978116, E2B_06024257.Organization: Health Canada
November 2024
Req # A-2022-001555
Adverse Drug Reactions (ADRs). Report numbers: 001020134, 001022815, E2B_05985461, E2B_05997808, E2B_06024320.Organization: Health Canada
November 2024
Req # A-2023-000292
Adverse Drug Reactions (ADRs) for TEMODAL. Report numbers: E2B_03132734, E2B_03147294, E2B_03113384, E2B_03138585, E2B_00327688, E2B_03233229. ADRs for VARIVAX III. Report numbers: E2B_02804158, 000679874. ADRs for ZOLINZA. Report numbers:…Organization: Health Canada
November 2024
Req # A-2023-000335
Adverse Drug Reactions (ADRs) for DEXILANT. Report numbers: E2B_06227430, E2B_06248993, 001032323, E2B_06249888. ADRs for ENTYVIO. Report numbers: E2B_06244726, E2B_06237252, E2B_06213586. ADR for IXAZOMIB. Report number: E2B_06242068. ADR for…Organization: Health Canada
November 2024
Req # A-2024-000101
Adverse Drug Reactions (ADRs) for Entyvio. Report numbers: E2B_06954186, 001075329. ADR for Vedolizumab. Report number: 001081570. ADR for Nesina. Report number: 001081180. ADR for Ixazomib. Report number: E2B_06922374. ADRs for Ondansetron.…Organization: Health Canada
November 2024
Req # A-2024-000181
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-108758-44.Organization: Health Canada
November 2024
Req # A-2024-000200
Adverse Drug Reactions (ADRs). Report numbers: 001081963, 001082532, 001081570, 001082478, 001075295, E2B_06959022, E2B_06850099, E2B_06931413, E2B_06938467, 001076647.Organization: Health Canada
November 2024
Req # A-2024-000217
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 24-100656-5, Letter to British Columbia's Minister of Mental Health and Addictions Regarding Personal Possession Exemption.Organization: Health Canada
November 2024